SCHEMBL3102701

SCHEMBL3102701

CCOC(=O)C(Cc1ccc(NC(=O)c2ccccc2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.49
NPY1R P25929 1/20 0.48
NPY2R P49146 1/20 0.48
MMP9 P14780 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
LMNA P02545 2/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
POLB P06746 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
GPR27 Q9NS67 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
GAA P10253 1/20 0.46
MMP8 P22894 1/20 0.46
LARS1 Q9P2J5 1/20 0.45
KAT6A Q92794 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093022 0.89 MMP9 (0.55) MMP9LMNANPC1RAB9AGPR27
SCHEMBL3091388 0.88 MMP8 (0.58) NPY1RNPY2RALDH1A1TP53LMNA
SCHEMBL3097275 0.86 MMP8 (0.51) ALDH1A1TP53POLBGAAMMP8
SCHEMBL3102970 0.86 MMP9 (0.46) MMP9ALDH1A1LMNANPC1RAB9A
SCHEMBL3093901 0.86 MMP9 (0.46) MMP9ALDH1A1LMNANPC1RAB9A
SCHEMBL3093748 0.86 LARS1 (0.54) NPY1RMMP9ALDH1A1TP53POLB
SCHEMBL3103341 0.86 MMP9 (0.48) MMP9ALDH1A1LMNANPC1RAB9A
SCHEMBL3092113 0.85 MMP9 (0.46) MMP9LMNANPC1RAB9APOLB
SCHEMBL3090460 0.85 MMP9 (0.49) MMP9LMNANPC1RAB9AGPR27
SCHEMBL3100522 0.85 MMP9 (0.45) MMP9LMNAGPR27LARS1KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 AR 200/4885NPY1R 1344/4885NPY2R 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.